Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Williams, Katrina ^a,b,c   Brignell, Amanda ^a   Randall, Melinda ^a   Silove, Natalie ^d   Hazell, Philip ^e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AGGRESSION; ANXIETY; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COMMUNICATION DISORDER; COMMUNICATION SKILL; COMORBIDITY; DEPRESSION; DRUG EFFECT; DRUG INDICATION; DRUG WITHDRAWAL; FLATULENCE; HUMAN; LIBIDO DISORDER; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEIZURE; SOCIAL INTERACTION; SOMNOLENCE; STEREOTYPY; SYSTEMATIC REVIEW; ADULT; AGE; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE FACTORS; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CITALOPRAM; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 84893391547     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004677.pub3     Document Type: Review

References (59)

1. Barthelemy C, Bruneau N, Jouve J, Martineau J, Muh JP, Lelord G. Urinary dopamine metabolites as indicators of the responsiveness of fenfluramine treatment in children with autistic behavior. Journal of Autism and Developmental Disorders 1989;19(2):241-54.
2. Buchsbaum M, Hollander E, Haznedar M, Tong C, Spiegal-Cohen J, Wei T, et al. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. International Journal of Neuropsychopharmacology 2001;4(2):119-25.
3. Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology 2005;30(3):582-9.
4. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. American Journal of Psychiatry 2012;169(3):292-9.
5. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior. Archives of General Psychiatry 2009;66(6):583-90.
6. Leventhal B, Cook E, Morford M, Ravitz A, Heller W, Freedman D. Clinical and neurochemical effects of fenfluramine in children with autism. Journal of Neuropsychiatry 1993;5(3):307-15.
7. McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry 1996;53(11):1001-8.
8. Dichter GS. Functional MRI evaluation of the effect of citalopram in autism spectrum disorders. University of North Carolina, Chapel Hill Registered in 2008. [NCT00609531]
9. Sugie Y, Sugie H, Kukuda T, Ito M, Sasada Y, Nakabayashi M, et al. Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism. Journal of Autism and Developmental Disorders 2005;35(3):377-85.
10. Doyle J, Casciano J, Arikan S, Tarride JE, Gonzales M, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in Health 2001;4(1):16-31.
11. Gordon C, State R, Nelson J, Hamburger S, Rapoport J. A double-blind comparison of clomipramine, desipramine, and of autistic disorder. Archives of General Psychiatry 1993;50(6):441-7.
12. Humble M, Bejerot S, Bergqvist P, Bengtsson F. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. Biological Psychiatry 2001;49(4):360-8.
13. McDougle C, Brodkin E, Naylor S, Carlson D, Cohen D, Price L. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. Journal of Clinical Psychopharmacology 1998;18(1):62-6.
14. Peral M, Alcami M, Gilaberte I. Fluoxetine in children with autism. Journal of the American Academy of Child and Adolescent Psychiatry 1999;38(12):1472-3.
15. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, cross-over study. Journal of Clinical Psychopharmacology 2001;21(4):440-4.
16. Sanchez L, Campbell M, Small A, Cueva J, Armenteros J, Adams P. A pilot study of clomipramine in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35(4):537-44.
17. Scahill L, McCraken JT, Bearss K, Robinson F, Hollander E, King B, et al. Design and subject characteristics in the federally funded citalopram trial in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders 2011;42(3):432-40. [DOI:]
18. Assistance Publique - Hopitaux De Paris (AP-HP). [Etude de la réponse clinique et neurofonctionelle a la fluoxetine dans l'autisme infantile - FAIR]. EU Clinical Trials Register (www.clinicaltrialsregister.eu/ctr-search/trial/2008-003712-36/FR/) (accessed 19 March 2013) Registered 28 November 2008.
19. Sikich L. Effectiveness of early intervention with fluoxetine in enhancing developmental processes in children with autism (STAART Study 2). ClinicalTrials.gov (clinicaltrials.gov/ct2/show/NCT00183339) (accessed 19 March 2013) Registered 2005.
20. Neuropharm. Study of fluoxetine in autism (SOFIA). ClinicalTrials.gov (clinicaltrials.gov/show/NCT00515320) (accessed 19 March 2013) Registered August 2007.
21. Roberts W. A double-blind placebo-controlled randomized clinical trial of fluvoxamine and sertraline in childhood autism - Does SSRI therapy improve behaviour and/or mood?. ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT00655174) (accessed 19 March 2013) Registered 4 April 2008.
22. Virasinghe R. Fluoxetine for the treatment of repetitive behaviours in children and adolescents with autism: a randomised double-blind placebo-controlled trial. Australian New Zealand Trials Registry (www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12608000173392) (accessed 19 March 2013) Prospectively registered in 2008.
23. Aman MG, Lam KSL, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology 2005;15(1):116-26.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. American Psychiatric Association, 1980.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. American Psychiatric Association, 1987.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, 1994.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. American Psychiatric Association, 2013.
28. Billstedt E, Gillberg IC, Gillberg C. Autism after adolescence: population-based 13-to 22-year follow-up study of 120 individuals with autism diagnosed in childhood. Journal of Autism and Developmental Disorders 2005;35(3):351-60.
29. Bodfish JW, Symons FW, Lewis MH. The Repetitive Behavior Scale. Morganton, NC: Western Carolina Center Research Reports, 1999.
30. Branford D, Bhaumik S, Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. Journal of Intellectual Disability Research 1998;42(4):301-6.
31. Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. Morbidity and Mortality Weekly Report 2012;61(3):1-19.
32. Cook EH, Leventhal BL. The serotonin system in autism. Current Opinion in Pediatrics 1996;8(4):348-54.
33. Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcín C, et al. Global prevalence of autism and other pervasive developmental disorders. Autism Research 2012;5(3):160-79. [DOI:]
34. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman RL, Hill CL, et al. The Yale-Brown Obsessive Compuslive Scale. I. Development, use, and reliability. Archives of General Psychiatry 1989;46(11):1006-11.
35. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 1989;46(11):1012-6.
36. Greenhill LL, Vitiello B, Fisher P, Levine J, Davies M, AbikoffH, et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(12):1488-96.
37. Gringras P. Practical paediatric psychopharmacological prescribing in autism. Autism 2000;4(3):229-47.
38. Guy W. ECDEU Assessment Manual for Psychopharmacology. Bethesda, MD: National Institute of Mental Health, 1976.
39. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
40. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
41. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. Journal of Child Psychology and Psychiatry and Allied Disciplines 2004;45(2):212-29.
42. Hurwitz R, Blackmore R, Hazell P, Williams K, Woolfenden S. Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI:]
43. Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI:]
44. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America 2006;15(1):161-75.
45. Lefebvre C, Manheinmer E, Glanville J (editors). Chapter 6: Searching for Studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester, UK: John Wiley & Sons.
46. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics 2008;121(3):e441-8.
47. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine 2002;347(5):314-21.
48. McKay D, Piacentinib J, Greisberga S, Graaec F, Jafferc M, Millerc J, et al. The Children's Yale-Brown Obsessive-Compulsive Scale: item structure in an outpatient setting. Psychological Assessment 2003;15(4):578-81.
49. Murray ML, Wong ICK, Thompson M. Do selective serotonin reuptake inhibitors cause suicide? Antidepressant prescribing to children and adolescents by GPs has fallen since CSM advice. BMJ 2005;330(7500):1151.
50. NemeroffCB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Archives of General Psychiatry 2007;64(4):466-72.
51. Oswald DP, Sonenklar NA. Medication use among children with autism-spectrum disorders. Journal of Child and Adolescent Psychopharmacology 2007;17(3):348-55.
52. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
53. Rosenberg RE, Mandell DS, Farmer JE, Law JK, Marvin AR, Law PA. Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008. Journal of Autism and Developmental Disorders 2010;40:342-52.
54. Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacology and Therapeutics 1995;66(2):339-68.
55. Scahill L, McDougle CJ, Williams SK, Dimitropoulos A, Aman MG, McCracken JT, et al. The Children's Yale-Brown Obsessive Compulsive Scales modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(9):1114-23.
56. Sinha Y, Silove N, Hayen A, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI:]
57. World Health Organization. International Classification of Diseases (ICD-10). World Health Organization, 1993.
58. Williams JG, Higgins JPT, Brayne CEG. Systematic review of prevalence studies of autism spectrum disorders. Archives of Diseases in Childhood 2006;91(1):8-15. [DOI:]
59. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2010, Issue 8. [DOI:]